Zacks Research Comments on Henry Schein, Inc.’s FY2024 Earnings (NASDAQ:HSIC)

Henry Schein, Inc. (NASDAQ:HSIC) – Stock analysts at Zacks Research increased their FY2024 earnings per share estimates for shares of Henry Schein in a research report issued to clients and investors on Tuesday, April 16th. Zacks Research analyst U. Biswas now forecasts that the company will post earnings of $5.04 per share for the year, up from their prior estimate of $5.03. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2025 earnings at $1.37 EPS and FY2025 earnings at $5.38 EPS.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The business had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. During the same quarter last year, the firm posted $1.21 EPS. The company’s revenue was down 10.5% compared to the same quarter last year.

Other research analysts have also issued research reports about the company. Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. Jefferies Financial Group upped their price objective on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, March 6th. JPMorgan Chase & Co. upped their price objective on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Evercore ISI upped their price objective on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a report on Wednesday, February 28th. Finally, SVB Leerink began coverage on Henry Schein in a report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price objective for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $81.09.

Henry Schein Trading Down 0.3 %

Shares of HSIC stock opened at $69.97 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. Henry Schein has a 1 year low of $60.01 and a 1 year high of $85.39. The stock has a fifty day moving average of $74.43 and a two-hundred day moving average of $72.48. The firm has a market capitalization of $8.99 billion, a PE ratio of 22.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87.

Insider Transactions at Henry Schein

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HSIC. Boston Partners increased its position in Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after purchasing an additional 1,556,831 shares during the last quarter. Norges Bank acquired a new position in Henry Schein in the 4th quarter worth about $111,715,000. Morgan Stanley increased its position in Henry Schein by 143.4% in the 4th quarter. Morgan Stanley now owns 2,337,890 shares of the company’s stock worth $186,727,000 after purchasing an additional 1,377,207 shares during the last quarter. Nuance Investments LLC bought a new stake in shares of Henry Schein during the 4th quarter worth about $103,446,000. Finally, Lazard Asset Management LLC boosted its stake in shares of Henry Schein by 1,303.3% during the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after acquiring an additional 1,158,451 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.